(Total Views: 838)
Posted On: 12/17/2020 5:36:02 AM
Post# of 148898
“Penny Stocks to Watch #1: CytoDyn Inc.
CytoDyn Inc. is considered to be a late-stage biotech company working on the commercialization and development of several novel drugs. This includes its leading product which is known as Pro-140. This substance is used as an anti-viral agent against HIV and breast cancer. Currently, the company is in several Phase I/II trails for this substance. In addition, the company is working on its drug known as leronlimab for its use in treating patients with Covid. On December 15th, the company announced that it is working on a Phase 3 trial of this drug for severe covid patients. The trial, which has 390 patients, should produce results within the next month or so.
Nader Pourhassan, CEO of the company, stated that “we are very thankful for the concerted efforts by so many healthcare professionals to reach full enrollment so quickly in these trying times. To the best of our knowledge, we are the first company to complete a Phase 3 trial for Covid-19 severe-to-critical population.”
This is a major step for both dealing with covid and for CytoDyn as a company. With results potentially coming in the short term, it looks like CytoDyn has a lot to look forward to in 2021. Additionally, as a biotech company, CYDY stock has a steep correlation with any news that comes out about covid. With this in mind, investors can decide if CYDY stock is a penny stock to watch this month. “
https://pennystocks.com/featured/2020/12/16/l...r-16-2020/
CytoDyn Inc. is considered to be a late-stage biotech company working on the commercialization and development of several novel drugs. This includes its leading product which is known as Pro-140. This substance is used as an anti-viral agent against HIV and breast cancer. Currently, the company is in several Phase I/II trails for this substance. In addition, the company is working on its drug known as leronlimab for its use in treating patients with Covid. On December 15th, the company announced that it is working on a Phase 3 trial of this drug for severe covid patients. The trial, which has 390 patients, should produce results within the next month or so.
Nader Pourhassan, CEO of the company, stated that “we are very thankful for the concerted efforts by so many healthcare professionals to reach full enrollment so quickly in these trying times. To the best of our knowledge, we are the first company to complete a Phase 3 trial for Covid-19 severe-to-critical population.”
This is a major step for both dealing with covid and for CytoDyn as a company. With results potentially coming in the short term, it looks like CytoDyn has a lot to look forward to in 2021. Additionally, as a biotech company, CYDY stock has a steep correlation with any news that comes out about covid. With this in mind, investors can decide if CYDY stock is a penny stock to watch this month. “
https://pennystocks.com/featured/2020/12/16/l...r-16-2020/
(0)
(0)Scroll down for more posts ▼
